| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT07251582 Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in… |
Enrollment increased: 156 -> 186 participants |
| 2026-08-09 | NCT05991206 A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet… |
overall status: Recruiting → Unknown |
| 2026-07-22 | NCT06477055 The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell… |
Trial completed |
| 2026-07-22 | NCT06477055 The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell… |
Enrollment reduced: 60 -> 43 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05055908 | Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint… | Lung Cancer | Recruiting |
| NCT07251582 | Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in… | Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line… | Non Small Cell Lung Cancer | Not Yet Recruiting |
| NCT07477808 | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| Phase 2 | |||
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent… | ALK Gene Mutation | Recruiting |
| NCT05584267 | Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation… | Non Small Cell Lung Cancer | Recruiting |
| NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | Non-Small Cell Lung Cancer | Recruiting |
| NCT05284539 | Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for… | Non Small Cell Lung Cancer | Recruiting |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | Small-cell Lung Cancer | Recruiting |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for… | Non Small Cell Lung Cancer | Recruiting |
| NCT05379803 | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06348927 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With… | Non-Small Cell Lung Cancer | Recruiting |
| NCT05014464 | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma | Non-small Cell Lung Cancer | Recruiting |
| NCT06355609 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW | Non-small Cell Lung Cancer | Recruiting |
| NCT04322890 | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic… | Non Small Cell Lung Cancer | Recruiting |
| NCT04777084 | The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06497543 | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or… | Small-cell Lung Cancer | Not Yet Recruiting |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway… | Non-Small Cell Lung Cancer | Not Yet Recruiting |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC… | Non-small Cell Lung Cancer | Not Yet Recruiting |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell… | Non-small Cell Lung Cancer | Not Yet Recruiting |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation… | Small Cell Lung Cancer | Not Yet Recruiting |
| NCT06706219 | Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab… | Non Small Cell Lung Cancer (Stage III) | Not Yet Recruiting |
| NCT07662473 | The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With… | NSCLC | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06081907 | The Efficacy and Safety of IBI363 in Solid Tumors | Advanced Solid Tumor | Recruiting |